GLP1R and coronary artery disorder: Peptides such as glucagon-like peptide-1 (GLP-1) analogs, Nesiritide, and Apelin are either approved for clinical use or undergoing trials for CAD treatment, demonstrating their relevance as effective therapeutic agents [10,11].